Understanding and Preventing Cortical Mechanisms of Chemotherapy-induced Peripheral Neuropathy
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorM.D. Anderson Cancer Center
About this trial
Cohort 1: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN).
Cohort 2: To track the onset and progression of a condition called chemotherapy-induced peripheral neuropathy (CIPN) and to test a certain type of experimental neuromodulation (stimulation of the brain) with a device called a closed-loop brain-computer interface (clBCI) to see if can help to prevent pain due to CIPN.
Eligibility criteria
Qualifiers
Participants must have the ability to understand and read English, sign a written informed consent, and be willing to follow protocol requirements.
ECOG Performance Status of 0-2;
Willing to come to MD Anderson for the imaging sessions.
Are 18 years of age or above.
Disqualifiers
Participants who are taking any antipsychotic medications.
With active CNS disease, such as clinically evident metastases or leptomeningeal disease, dementia, or encephalopathy.
Have ever been diagnosed with bipolar disorder or schizophrenia.
Known, previously diagnosed peripheral neuropathy from any causes and
Trial design
Treatments tested in this trial
- Electroencephalogram (EEG)
Treatment groups
45 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov